[P02BB01, trichlorfon, The therapeutic efficacy of Metrifonate can be decreased when used in combination with Dipyridamole.]
[S02DA03, antipyrine, The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Dipyridamole.]
[G03XB02, ulipristal, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Ulipristal.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Dipyridamole is combined with Streptokinase.]
[L01AD04, streptozocin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Streptozocin.]
[J01EC01, sulfamethoxazole, Dipyridamole may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dipyridamole.]
[M01AB02, sulindac, The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Dipyridamole.]
[N05AL01, sulpiride, The therapeutic efficacy of Sulpiride can be decreased when used in combination with Dipyridamole.]
[M01AX04, apazone, The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Dipyridamole.]
[L01BB02, mercaptopurine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Mercaptopurine.]
[N06DA01, tacrine, The therapeutic efficacy of Tacrine can be decreased when used in combination with Dipyridamole.]
[L02BA01, tamoxifen, The risk or severity of bleeding can be increased when Tamoxifen is combined with Dipyridamole.]
[L01CB02, teniposide, The risk or severity of bleeding can be increased when Dipyridamole is combined with Teniposide.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Dipyridamole.]
[B01AE07, dabigatran etexilate, Dabigatran etexilate may increase the anticoagulant activities of Dipyridamole.]
[G03BA03, testosterone, Testosterone may increase the anticoagulant activities of Dipyridamole.]
[J01DI02, ceftaroline fosamil, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Ceftaroline fosamil.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Dipyridamole.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Thalidomide.]
[L01XX41, eribulin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Eribulin.]
[L01AC01, thiotepa, The therapeutic efficacy of Thiotepa can be decreased when used in combination with Dipyridamole.]
[L01BB03, thioguanine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Tioguanine.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Dipyridamole.]
[N05AB08, thioproperazine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Thioridazine.]
[B02AB01, aprotinin, The therapeutic efficacy of Aprotinin can be decreased when used in combination with Dipyridamole.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Dipyridamole.]
[S01ED01, timolol, Dipyridamole may increase the bradycardic activities of Timolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[M02AX02, tolazoline, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Tolazoline.]
[M02AA21, tolmetin, The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Dipyridamole.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Dipyridamole.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Dipyridamole.]
[N06AX05, trazodone, The risk or severity of bleeding can be increased when Trazodone is combined with Dipyridamole.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Dipyridamole.]
[S01BA05, triamcinolone, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Triamcinolone.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Dipyridamole.]
[C03AA06, trichlormethiazide, Dipyridamole may increase the antihypertensive activities of Trichlormethiazide.]
[S01EB04, demecarium, The therapeutic efficacy of Demecarium can be decreased when used in combination with Dipyridamole.]
[N05AB06, trifluoperazine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Trifluoperazine.]
[N05AA05, triflupromazine, The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Dipyridamole.]
[S01ED04, metipranolol, The risk or severity of hypotension can be increased when Dipyridamole is combined with Metipranolol.]
[C02BA01, trimethaphan, Dipyridamole may increase the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Trimipramine.]
[C09CA09, azilsartan medoxomil, Dipyridamole may increase the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The therapeutic efficacy of Tubocurarine can be decreased when used in combination with Dipyridamole.]
[S01AA05, tyrothricin, The therapeutic efficacy of Tyrothricin can be decreased when used in combination with Dipyridamole.]
[B01AD04, urokinase, Urokinase may increase the anticoagulant activities of Dipyridamole.]
[B01AF01, rivaroxaban, Dipyridamole may increase the anticoagulant activities of Rivaroxaban.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Dipyridamole is combined with Ticagrelor.]
[C08DA01, verapamil, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Verapamil.]
[L01CA01, vinblastine, Vinblastine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[C04AX07, vincamine, Dipyridamole may increase the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, Vincristine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[L01CA03, vindesine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Vindesine.]
[A11HA03, vitamin E, Vitamin E may increase the antiplatelet activities of Dipyridamole.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Warfarin.]
[C03BA10, xipamide, Dipyridamole may increase the antihypertensive activities of Xipamide.]
[J05AF01, zidovudine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Zuclopenthixol.]
[J05AE02, indinavir, Indinavir may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Lepirudin.]
[N05AE04, ziprasidone, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Ziprasidone.]
[G03AC10, drospirenone, The risk or severity of adverse effects can be increased when Drospirenone is combined with Dipyridamole.]
[L04AA34, alemtuzumab, The risk or severity of bleeding can be increased when Dipyridamole is combined with Alemtuzumab.]
[L01EJ01, ruxolitinib, The risk or severity of bleeding can be increased when Dipyridamole is combined with Ruxolitinib.]
[C07AB03, atenolol, Dipyridamole may increase the bradycardic activities of Atenolol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of bleeding can be increased when Dipyridamole is combined with Peginterferon alfa-2a.]
[L01FA01, rituximab, The risk or severity of bleeding can be increased when Dipyridamole is combined with Rituximab.]
[S01FA01, atropine, Atropine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[L01EK01, axitinib, The excretion of Axitinib can be decreased when combined with Dipyridamole.]
[L01BC07, azacitidine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Azacitidine.]
[L01BC05, gemcitabine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Gemcitabine.]
[G04BE10, avanafil, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Avanafil.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Gemtuzumab ozogamicin.]
[L01XG02, carfilzomib, The risk or severity of bleeding can be increased when Dipyridamole is combined with Carfilzomib.]
[L01EA04, bosutinib, The risk or severity of bleeding can be increased when Dipyridamole is combined with Bosutinib.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Dipyridamole is combined with Defibrotide.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Dipyridamole.]
[J05AE04, nelfinavir, Nelfinavir may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[L01AA09, bendamustine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Bendamustine.]
[S01GA07, brimonidine, The risk or severity of hypotension can be increased when Dipyridamole is combined with Brimonidine.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Dipyridamole.]
[C08CA13, lercanidipine, Dipyridamole may increase the antihypertensive activities of Lercanidipine.]
[N06DA02, donepezil, The therapeutic efficacy of Donepezil can be decreased when used in combination with Dipyridamole.]
[L04AA29, tofacitinib, The risk or severity of bleeding can be increased when Dipyridamole is combined with Tofacitinib.]
[G04BE03, sildenafil, The risk or severity of hemorrhage can be increased when Dipyridamole is combined with Sildenafil.]
[L01EA05, ponatinib, The risk or severity of bleeding can be increased when Dipyridamole is combined with Ponatinib.]
[B01AF02, apixaban, Apixaban may increase the anticoagulant activities of Dipyridamole.]
[C03AA01, bendroflumethiazide, Dipyridamole may increase the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of bleeding can be increased when Dipyridamole is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Dipyridamole.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Canagliflozin.]
[M04AB03, benzbromarone, Dipyridamole may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[J02AX04, caspofungin, The excretion of Caspofungin can be decreased when combined with Dipyridamole.]
[M01AH01, celecoxib, The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Dipyridamole.]
[L04AA18, everolimus, The risk or severity of bleeding can be increased when Dipyridamole is combined with Everolimus.]
[R02AX03, benzydamine, The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Dipyridamole.]
[N06AX28, levomilnacipran, The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Dipyridamole.]
[C08EA02, bepridil, Dipyridamole may increase the antihypertensive activities of Bepridil.]
[C02KX05, riociguat, Dipyridamole may increase the hypotensive activities of Riociguat.]
[A05AA03, cholic acid, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Cholic Acid.]
[C02KX04, macitentan, Dipyridamole may increase the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dipyridamole.]
[N06AX26, vortioxetine, The risk or severity of bleeding can be increased when Vortioxetine is combined with Dipyridamole.]
[G03AC08, etonogestrel, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Etonogestrel.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[S01EA03, apraclonidine, The risk or severity of hypotension can be increased when Dipyridamole is combined with Apraclonidine.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Dapagliflozin.]
[C07AB04, acebutolol, Dipyridamole may increase the bradycardic activities of Acebutolol.]
[A16AA06, betaine, The therapeutic efficacy of Betaine can be decreased when used in combination with Dipyridamole.]
[S01ED02, betaxolol, Dipyridamole may increase the bradycardic activities of Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Dipyridamole is combined with Argatroban.]
[C02CC01, bethanidine, Dipyridamole may increase the antihypertensive activities of Bethanidine.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Dipyridamole.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Dipyridamole is combined with Acenocoumarol.]
[L01XH04, belinostat, The risk or severity of bleeding can be increased when Dipyridamole is combined with Belinostat.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Empagliflozin.]
[L03AB13, peginterferon beta-1a, The risk or severity of bleeding can be increased when Dipyridamole is combined with Peginterferon beta-1a.]
[N05AA04, acepromazine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Acepromazine.]
[L01BC08, decitabine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Decitabine.]
[L01EX09, nintedanib, The risk or severity of bleeding can be increased when Nintedanib is combined with Dipyridamole.]
[L01FX07, blinatumomab, The risk or severity of bleeding can be increased when Dipyridamole is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of bleeding can be increased when Dipyridamole is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dipyridamole is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Dipyridamole.]
[L01EF01, palbociclib, The risk or severity of bleeding can be increased when Dipyridamole is combined with Palbociclib.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Dipyridamole is combined with Tioclomarol.]
[J05AP06, asunaprevir, The excretion of Asunaprevir can be decreased when combined with Dipyridamole.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Dipyridamole.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Dipyridamole is combined with Cangrelor.]
[N05AX16, brexpiprazole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Brexpiprazole.]
[M02AA25, aceclofenac, The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Dipyridamole.]
[M01AB11, acemetacin, The risk or severity of bleeding and hemorrhage can be increased when Dipyridamole is combined with Acemetacin.]
[L01CX01, trabectedin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Trabectedin.]
[J05AF13, tenofovir alafenamide, The excretion of Tenofovir alafenamide can be decreased when combined with Dipyridamole.]
[V03AB35, sugammadex, The risk or severity of bleeding and hemorrhage can be increased when Dipyridamole is combined with Sugammadex.]
[B01AC27, selexipag, Dipyridamole may increase the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Alfuzosin.]
[J05AP11, grazoprevir, The excretion of Grazoprevir can be decreased when combined with Dipyridamole.]
[M01AE16, alminoprofen, The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Dipyridamole.]
[N02BA02, aloxiprin, The risk or severity of bleeding can be increased when Aloxiprin is combined with Dipyridamole.]
[N04BC01, bromocriptine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Bromocriptine.]
[C08CA01, amlodipine, Dipyridamole may increase the antihypertensive activities of Amlodipine.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Obeticholic acid.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Bumetanide is combined with Dipyridamole.]
[S01ED03, levobunolol, The risk or severity of hypotension can be increased when Dipyridamole is combined with Levobunolol.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dipyridamole.]
[C07AA19, bupranolol, Dipyridamole may increase the bradycardic activities of Bupranolol.]
[L01AB01, busulfan, The risk or severity of bleeding can be increased when Dipyridamole is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Dipyridamole.]
[S01AA26, azithromycin, The risk or severity of adverse effects can be increased when Azithromycin is combined with Dipyridamole.]
[A07EC04, balsalazide, The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Dipyridamole.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Dipyridamole.]
[C09AA07, benazepril, Dipyridamole may increase the antihypertensive activities of Benazepril.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Dipyridamole.]
[J05AE09, tipranavir, Tipranavir may increase the antiplatelet activities of Dipyridamole.]
[H03BA03, benzylthiouracil, Benzylthiouracil may increase the anticoagulant activities of Dipyridamole.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Dipyridamole.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Dipyridamole is combined with Betrixaban.]
[L01BC06, capecitabine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Capecitabine.]
[L01XH01, vorinostat, The risk or severity of bleeding can be increased when Dipyridamole is combined with Vorinostat.]
[C07AB07, bisoprolol, Dipyridamole may increase the bradycardic activities of Bisoprolol.]
[J05AG03, efavirenz, Efavirenz may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[J01DC10, cefprozil, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefprozil.]
[C07AA17, bopindolol, Dipyridamole may increase the bradycardic activities of Bopindolol.]
[L01BA03, raltitrexed, The risk or severity of bleeding can be increased when Dipyridamole is combined with Raltitrexed.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Nesiritide.]
[R03BA02, budesonide, Dipyridamole may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Dipyridamole.]
[M01AB07, bumadizone, The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Dipyridamole.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[B02BX06, emicizumab, The therapeutic efficacy of Emicizumab can be decreased when used in combination with Dipyridamole.]
[N01BX04, capsaicin, The therapeutic efficacy of Capsaicin can be decreased when used in combination with Dipyridamole.]
[C09AA01, captopril, Dipyridamole may increase the antihypertensive activities of Captopril.]
[N03AF01, carbamazepine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Carbamazepine.]
[H03BB01, carbimazole, Carbimazole may increase the anticoagulant activities of Dipyridamole.]
[L03AB06, interferon alfa-n1, The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon alfa-n1.]
[C07AG02, carvedilol, Dipyridamole may increase the bradycardic activities of Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Fostamatinib.]
[V03AB38, andexanet alfa, The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Dipyridamole.]
[J01DE01, cefepime, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefepime.]
[J01DD10, cefetamet, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefetamet.]
[J01DD09, cefodizime, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefodizime.]
[J01DC11, ceforanide, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Ceforanide.]
[J01DD13, cefpodoxime, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefpodoxime.]
[J01DD14, ceftibuten, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Ceftibuten.]
[C07AB08, celiprolol, Dipyridamole may increase the bradycardic activities of Celiprolol.]
[H01CC03, elagolix, The excretion of Elagolix can be decreased when combined with Dipyridamole.]
[M01AC05, lornoxicam, The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Dipyridamole.]
[R03BB08, revefenacin, Dipyridamole may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01AD01, carmustine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Carmustine.]
[C09AA08, cilazapril, Dipyridamole may increase the antihypertensive activities of Cilazapril.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Dipyridamole.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Dipyridamole.]
[S01ED05, carteolol, The risk or severity of hypotension can be increased when Dipyridamole is combined with Carteolol.]
[J01FA09, clarithromycin, Dipyridamole may decrease the excretion rate of Clarithromycin which could result in a higher serum level.]
[C09CA06, candesartan, Dipyridamole may increase the antihypertensive activities of Candesartan.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[J01DB05, cefadroxil, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefadroxil.]
[J01DC03, cefamandole, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefamandole.]
[J01DB07, cefatrizine, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefatrizine.]
[J01DB04, cefazolin, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefazolin.]
[J01DC09, cefmetazole, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefmetazole.]
[J01DC06, cefonicid, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefonicid.]
[J01DD12, cefoperazone, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefoperazone.]
[J01DD01, cefotaxime, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefotaxime.]
[J01DC05, cefotetan, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefotetan.]
[J01DC07, cefotiam, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefotiam.]
[J01DC01, cefoxitin, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefoxitin.]
[J01DD03, cefsulodin, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefsulodin.]
[J01DD02, ceftazidime, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Ceftazidime.]
[C03BX03, cicletanine, Dipyridamole may increase the antihypertensive activities of Cicletanine.]
[J01DD07, ceftizoxime, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Ceftizoxime.]
[J01DD04, ceftriaxone, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Ceftriaxone.]
[S01AA27, cefuroxime, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefuroxime.]
[C03AA09, cyclothiazide, Dipyridamole may increase the antihypertensive activities of Cyclothiazide.]
[J01DB01, cephalexin, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cephalexin.]
[J01DB02, cephaloridine, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefaloridine.]
[J01DB03, cephalothin, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefalotin.]
[J01DB08, cephapirin, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefapirin.]
[J01DB09, cephradine, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefradine.]
[G03DB05, demegestone, The risk or severity of adverse effects can be increased when Demegestone is combined with Dipyridamole.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Trastuzumab emtansine.]
[G03AC09, desogestrel, The risk or severity of adverse effects can be increased when Desogestrel is combined with Dipyridamole.]
[C10AX15, bempedoic acid, The excretion of Bempedoic acid can be decreased when combined with Dipyridamole.]
[G03DB08, dienogest, The risk or severity of adverse effects can be increased when Dienogest is combined with Dipyridamole.]
[M01AH02, rofecoxib, The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Dipyridamole.]
[L01XF03, bexarotene, The risk or severity of bleeding can be increased when Dipyridamole is combined with Bexarotene.]
[C08CA16, clevidipine, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Clevidipine.]
[C01BD07, dronedarone, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Dronedarone.]
[L01AA02, chlorambucil, The risk or severity of bleeding can be increased when Dipyridamole is combined with Chlorambucil.]
[S03AA08, chloramphenicol, The risk or severity of bleeding can be increased when Dipyridamole is combined with Chloramphenicol.]
[C02AA06, methoserpidine, Dipyridamole may increase the antihypertensive activities of Methoserpidine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Opicapone.]
[M01AC04, droxicam, The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Dipyridamole.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Dipyridamole.]
[C08CA17, levamlodipine, Dipyridamole may increase the antihypertensive activities of Levamlodipine.]
[L01FX15, belantamab mafodotin, Dipyridamole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[C03AA04, chlorothiazide, Dipyridamole may increase the antihypertensive activities of Chlorothiazide.]
[G03CA06, chlorotrianisene, Chlorotrianisene may decrease the anticoagulant activities of Dipyridamole.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Dipyridamole.]
[C03BA04, chlorthalidone, Dipyridamole may increase the antihypertensive activities of Chlorthalidone.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Dipyridamole.]
[N02BA07, ethenzamide, The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Dipyridamole.]
[N02BA03, choline salicylate, The risk or severity of bleeding can be increased when Choline salicylate is combined with Dipyridamole.]
[G03DC06, ethynodiol, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Etynodiol.]
[M01AB08, etodolac, The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Dipyridamole.]
[M02AA06, etofenamate, The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Dipyridamole.]
[L01BB05, fludarabine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Fludarabine.]
[C01DX22, vericiguat, The risk or severity of hypotension can be increased when Dipyridamole is combined with Vericiguat.]
[M01AE05, fenbufen, The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Dipyridamole.]
[C01CA19, fenoldopam, Dipyridamole may increase the antihypertensive activities of Fenoldopam.]
[J01DD08, cefixime, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefixime.]
[J01DD15, cefdinir, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefdinir.]
[S01JA01, fluorescein, Fluorescein may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The risk or severity of bleeding can be increased when Dipyridamole is combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Dipyridamole may increase the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[L01XA01, cisplatin, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Dipyridamole.]
[N06AB04, citalopram, The risk or severity of hemorrhage can be increased when Citalopram is combined with Dipyridamole.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Dipyridamole.]
[A10BB12, glimepiride, Glimepiride may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of bleeding can be increased when Dipyridamole is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The risk or severity of bleeding and thrombocytopenia can be increased when Dipyridamole is combined with Abrocitinib.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Dipyridamole is combined with Tenecteplase.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Levobupivacaine.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Clomipramine.]
[S01EA04, clonidine, Dipyridamole may increase the antihypertensive activities of Clonidine.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Dipyridamole.]
[A05BA08, glycyrrhizic acid, Dipyridamole may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[N05AH02, clozapine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Clozapine.]
[C02KB01, metyrosine, Dipyridamole may increase the antihypertensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Dipyridamole.]
[M03AC05, hexafluorenium, The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Dipyridamole.]
[L01XX40, omacetaxine mepesuccinate, The risk or severity of bleeding can be increased when Dipyridamole is combined with Omacetaxine mepesuccinate.]
[J01DE02, cefpirome, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefpirome.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Desflurane.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Dipyridamole.]
[L01BB07, nelarabine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Nelarabine.]
[B01AC10, indobufen, The risk or severity of bleeding and hemorrhage can be increased when Indobufen is combined with Dipyridamole.]
[M01AH03, valdecoxib, The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Dipyridamole.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dipyridamole.]
[M01AH04, parecoxib, The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Dipyridamole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Bemiparin.]
[M01AA06, kebuzone, The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Dipyridamole.]
[L01EA01, imatinib, Imatinib may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[C08CA09, lacidipine, Dipyridamole may increase the hypotensive activities of Lacidipine.]
[N07BC04, lofexidine, Dipyridamole may increase the antihypertensive activities of Lofexidine.]
[M01AB09, lonazolac, The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Dipyridamole.]
[R06AX13, loratadine, Loratadine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[M02AA31, loxoprofen, The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Dipyridamole.]
[J01DC08, loracarbef, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Loracarbef.]
[C09AA03, lisinopril, Dipyridamole may increase the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, Dipyridamole may increase the antihypertensive activities of Manidipine.]
[C07AA14, mepindolol, Dipyridamole may increase the bradycardic activities of Mepindolol.]
[C01EB10, adenosine, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Adenosine.]
[C03DA04, eplerenone, Dipyridamole may increase the antihypertensive activities of Eplerenone.]
[C03AA07, cyclopenthiazide, Dipyridamole may increase the antihypertensive activities of Cyclopenthiazide.]
[L01AA01, cyclophosphamide, The risk or severity of bleeding can be increased when Dipyridamole is combined with Cyclophosphamide.]
[N06AX07, minaprine, The therapeutic efficacy of Minaprine can be decreased when used in combination with Dipyridamole.]
[S01XA18, cyclosporine, Cyclosporine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Dipyridamole.]
[C09AA13, moexipril, Dipyridamole may increase the antihypertensive activities of Moexipril.]
[C10AA07, rosuvastatin, Dipyridamole may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.]
[M02AA02, mofebutazone, The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Dipyridamole.]
[M01AX22, morniflumate, The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Dipyridamole.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Conivaptan is combined with Dipyridamole.]
[C02AC05, moxonidine, Dipyridamole may increase the antihypertensive activities of Moxonidine.]
[L01BC01, cytarabine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Cytarabine.]
[G04BE09, vardenafil, The risk or severity of adverse effects can be increased when Vardenafil is combined with Dipyridamole.]
[M01AH05, etoricoxib, The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Dipyridamole.]
[L01AX04, dacarbazine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Dactinomycin.]
[L01DB02, daunorubicin, Daunorubicin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[C02CC04, debrisoquin, Dipyridamole may increase the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Dipyridamole.]
[M01AX01, nabumetone, The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Dipyridamole.]
[B02BD03, anti-inhibitor coagulant complex, The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Dipyridamole.]
[C07AB12, nebivolol, Dipyridamole may increase the bradycardic activities of Nebivolol.]
[N06AX06, nefazodone, The risk or severity of hemorrhage can be increased when Nefazodone is combined with Dipyridamole.]
[C01DX16, nicorandil, Dipyridamole may increase the hypotensive activities of Nicorandil.]
[G03DB04, nomegestrol, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Nomegestrol.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Dipyridamole is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of bleeding can be increased when Escitalopram is combined with Dipyridamole.]
[A07EC03, olsalazine, The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Dipyridamole.]
[C09XA02, aliskiren, Dipyridamole may increase the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Dipyridamole.]
[S03BA01, dexamethasone, Dexamethasone may increase the excretion rate of Dipyridamole which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB05, paroxetine, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Dipyridamole.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Clopidogrel is combined with Dipyridamole.]
[V03AH01, diazoxide, Dipyridamole may increase the antihypertensive activities of Diazoxide.]
[S02DA04, dibucaine, The therapeutic efficacy of Cinchocaine can be decreased when used in combination with Dipyridamole.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Diclofenamide.]
[S01BC03, diclofenac, The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Dipyridamole.]
[C02DG01, pinacidil, Dipyridamole may increase the antihypertensive activities of Pinacidil.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Pipamperone.]
[L01DC04, ixabepilone, The risk or severity of bleeding can be increased when Dipyridamole is combined with Ixabepilone.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Diethylcarbamazine can be decreased when used in combination with Dipyridamole.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the anticoagulant activities of Dipyridamole.]
[C08CA03, isradipine, Isradipine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N02BA11, diflunisal, The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Dipyridamole.]
[C01AA05, digoxin, Digoxin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[C02DB01, dihydralazine, Dipyridamole may increase the antihypertensive activities of Dihydralazine.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may decrease the anticoagulant activities of Dipyridamole.]
[C10AX09, ezetimibe, Ezetimibe may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Dipyridamole may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Dihydroergotamine.]
[L04AX04, lenalidomide, The risk or severity of bleeding can be increased when Dipyridamole is combined with Lenalidomide.]
[J05AE08, atazanavir, Dipyridamole may decrease the excretion rate of Atazanavir which could result in a higher serum level.]
[B01AC21, treprostinil, Treprostinil may increase the antiplatelet activities of Dipyridamole.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the anticoagulant activities of Dipyridamole.]
[C08DB01, diltiazem, Dipyridamole may increase the antihypertensive activities of Diltiazem.]
[N02BB04, propyphenazone, The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Dipyridamole.]
[M01AB14, proglumetacin, The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Dipyridamole.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Dipyridamole.]
[C09AA06, quinapril, Dipyridamole may increase the antihypertensive activities of Quinapril.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[M01AG01, mefenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Dipyridamole.]
[C01DA05, pentaerythritol tetranitrate, The risk or severity of hypotension can be increased when Dipyridamole is combined with Pentaerythritol tetranitrate.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Dipyridamole is combined with Drotrecogin alfa.]
[C09AA05, ramipril, Dipyridamole may increase the antihypertensive activities of Ramipril.]
[S01XA23, sirolimus, The risk or severity of bleeding can be increased when Dipyridamole is combined with Sirolimus.]
[N07AA03, distigmine, The therapeutic efficacy of Distigmine can be decreased when used in combination with Dipyridamole.]
[P03AA04, disulfiram, Disulfiram may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N05AX08, risperidone, Dipyridamole may increase the hypotensive activities of Risperidone.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dipyridamole.]
[L01XG01, bortezomib, The risk or severity of bleeding can be increased when Dipyridamole is combined with Bortezomib.]
[G04BE08, tadalafil, The risk or severity of adverse effects can be increased when Tadalafil is combined with Dipyridamole.]
[S01BC05, ketorolac, The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Dipyridamole.]
[C02KX02, ambrisentan, Dipyridamole may increase the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Dipyridamole.]
[N06AA12, doxepin, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Doxepin.]
[L01DB01, doxorubicin, Dipyridamole may decrease the excretion rate of Doxorubicin which could result in a higher serum level.]
[J01AA02, doxycycline, The risk or severity of bleeding can be increased when Doxycycline is combined with Dipyridamole.]
[N06AB06, sertraline, The risk or severity of bleeding can be increased when Sertraline is combined with Dipyridamole.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Droperidol.]
[A08AA10, sibutramine, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Dipyridamole.]
[C10AA01, simvastatin, Simvastatin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[C09AA11, spirapril, Dipyridamole may increase the antihypertensive activities of Spirapril.]
[G03DB01, dydrogesterone, Dydrogesterone may decrease the anticoagulant activities of Dipyridamole.]
[N02CC01, sumatriptan, The excretion of Sumatriptan can be decreased when combined with Dipyridamole.]
[V04CX07, edrophonium, The therapeutic efficacy of Edrophonium can be decreased when used in combination with Dipyridamole.]
[C07AB13, talinolol, Dipyridamole may increase the bradycardic activities of Talinolol.]
[J01CG02, tazobactam, The risk or severity of bleeding can be increased when Tazobactam is combined with Dipyridamole.]
[L01AX03, temozolomide, The risk or severity of bleeding can be increased when Dipyridamole is combined with Temozolomide.]
[M01AC02, tenoxicam, The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Dipyridamole.]
[G04CA03, terazosin, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Terazosin.]
[C07AA16, tertatolol, Dipyridamole may increase the bradycardic activities of Tertatolol.]
[G03CX01, tibolone, Tibolone may increase the anticoagulant activities of Dipyridamole.]
[C09AA02, enalapril, Dipyridamole may increase the antihypertensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Dipyridamole.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Dipyridamole.]
[L02BA02, toremifene, The risk or severity of bleeding can be increased when Toremifene is combined with Dipyridamole.]
[C03CA04, torsemide, Dipyridamole may increase the antihypertensive activities of Torasemide.]
[C09AA10, trandolapril, Dipyridamole may increase the antihypertensive activities of Trandolapril.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Dipyridamole is combined with Triflusal.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Troxerutin.]
[C02CA06, urapidil, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Urapidil.]
[L01CA04, vinorelbine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Vinorelbine.]
[N06AX16, venlafaxine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Venlafaxine.]
[C08CA12, mepirodipine, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Barnidipine.]
[L01DB03, epirubicin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Epirubicin.]
[C09AA15, zofenopril, Dipyridamole may increase the antihypertensive activities of Zofenopril.]
[M01AB04, zomepirac, The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Dipyridamole.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Dipyridamole is combined with Anistreplase.]
[L01XA02, carboplatin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Carboplatin.]
[C02AC02, guanfacine, Dipyridamole may increase the antihypertensive activities of Guanfacine.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Dipyridamole.]
[N02CA02, ergotamine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Ergotamine.]
[C01DA13, erythrityl tetranitrate, The risk or severity of hypotension can be increased when Dipyridamole is combined with Erythrityl tetranitrate.]
[S01AA17, erythromycin, The risk or severity of bleeding can be increased when Erythromycin is combined with Dipyridamole.]
[G03CA03, estradiol, The risk or severity of adverse effects can be increased when Estradiol is combined with Dipyridamole.]
[G03CC06, estriol, Estriol may decrease the anticoagulant activities of Dipyridamole.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the anticoagulant activities of Dipyridamole.]
[C10AA04, fluvastatin, The excretion of Fluvastatin can be decreased when combined with Dipyridamole.]
[L02AA03, ethinyl estradiol, The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Dipyridamole.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Amifostine.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Dipyridamole.]
[M01AC06, meloxicam, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Dipyridamole.]
[L01CB01, etoposide, The risk or severity of bleeding can be increased when Dipyridamole is combined with Etoposide.]
[L04AD02, tacrolimus, The risk or severity of bleeding can be increased when Dipyridamole is combined with Tacrolimus.]
[A02BA04, nizatidine, The therapeutic efficacy of Nizatidine can be decreased when used in combination with Dipyridamole.]
[R06AX11, astemizole, Astemizole may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[R06AX12, terfenadine, Terfenadine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N06AB08, fluvoxamine, The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Dipyridamole.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[B02BD08, factor VIIa, The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dipyridamole.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dipyridamole is combined with Dextran.]
[B02BD07, factor XIII, The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dipyridamole.]
[V03AF02, dexrazoxane, The risk or severity of bleeding can be increased when Dipyridamole is combined with Dexrazoxane.]
[A16AA01, levocarnitine, The therapeutic efficacy of Dipyridamole can be increased when used in combination with Levocarnitine.]
[C08CA02, felodipine, Dipyridamole may decrease the excretion rate of Felodipine which could result in a higher serum level.]
[M01AE04, fenoprofen, The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Dipyridamole.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Fibrinolysin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Dipyridamole.]
[L04AA40, cladribine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Cladribine.]
[N02BG04, floctafenine, The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Dipyridamole.]
[J01CF05, floxacillin, Flucloxacillin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[J02AX01, flucytosine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Flucytosine.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Dipyridamole.]
[L01BC09, floxuridine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Floxuridine.]
[L01BC02, fluorouracil, The risk or severity of bleeding can be increased when Dipyridamole is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Dipyridamole.]
[N05AF01, flupenthixol, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Flupentixol.]
[S01BC04, flurbiprofen, The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Dipyridamole.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Dipyridamole.]
[C03CA01, furosemide, Dipyridamole may increase the antihypertensive activities of Furosemide.]
[N06DA04, galantamine, The therapeutic efficacy of Galantamine can be decreased when used in combination with Dipyridamole.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Dipyridamole.]
[L01EA02, dasatinib, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dipyridamole.]
[G03XA02, gestrinone, The risk or severity of adverse effects can be increased when Gestrinone is combined with Dipyridamole.]
[L02AB03, gestronol, Gestonorone may decrease the anticoagulant activities of Dipyridamole.]
[A10BB01, glyburide, Glyburide may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[A10BB07, glipizide, Dipyridamole may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[M01AX05, glucosamine, Glucosamine may increase the antiplatelet activities of Dipyridamole.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dipyridamole.]
[C05AE01, nitroglycerin, The risk or severity of hypotension can be increased when Dipyridamole is combined with Nitroglycerin.]
[C02CA04, doxazosin, The risk or severity of hypotension can be increased when Dipyridamole is combined with Doxazosin.]
[L01EX02, sorafenib, The risk or severity of bleeding can be increased when Dipyridamole is combined with Sorafenib.]
[C07AB09, esmolol, Dipyridamole may increase the bradycardic activities of Esmolol.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Dipyridamole is combined with Fluindione.]
[C09AA09, fosinopril, Dipyridamole may increase the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Dipyridamole may increase the antihypertensive activities of Guanethidine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Halothane.]
[N05AH04, quetiapine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Quetiapine.]
[L01CE02, irinotecan, The risk or severity of bleeding can be increased when Dipyridamole is combined with Irinotecan.]
[B06AB01, hemin, Hemin may increase the anticoagulant activities of Dipyridamole.]
[C09CA01, losartan, Losartan may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Heparin.]
[G03DC01, allylestrenol, Allylestrenol may decrease the anticoagulant activities of Dipyridamole.]
[A07EC02, mesalamine, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dipyridamole.]
[L01XX03, altretamine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Altretamine.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Dipyridamole.]
[C08CA10, nilvadipine, Dipyridamole may increase the antihypertensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Dipyridamole.]
[C09AA04, perindopril, Dipyridamole may increase the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Dipyridamole may increase the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Dipyridamole may increase the antihypertensive activities of Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, Dipyridamole may increase the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Propiverine.]
[G03DA03, 17-alpha-hydroxyprogesterone, Hydroxyprogesterone may decrease the anticoagulant activities of Dipyridamole.]
[L01XX05, hydroxyurea, The risk or severity of bleeding can be increased when Dipyridamole is combined with Hydroxyurea.]
[C02AC06, rilmenidine, Dipyridamole may increase the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of bleeding can be increased when Ibuprofen is combined with Dipyridamole.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Dipyridamole is combined with Sodium citrate.]
[L01DB06, idarubicin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of bleeding can be increased when Ifosfamide is combined with Dipyridamole.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Dipyridamole.]
[N06AA02, imipramine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Imipramine.]
[L01CD01, paclitaxel, Paclitaxel may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Dipyridamole.]
[L01CE01, topotecan, The risk or severity of bleeding can be increased when Dipyridamole is combined with Topotecan.]
[C03BA11, indapamide, Dipyridamole may increase the antihypertensive activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Dipyridamole.]
[C02CA02, indoramin, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Indoramin.]
[L03AB04, interferon alfa-2a, The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of hemorrhage can be increased when Milnacipran is combined with Dipyridamole.]
[D03BA02, collagenase, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Collagenase clostridium histolyticum.]
[C10AA06, cerivastatin, Cerivastatin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Dipyridamole.]
[C07AA01, alprenolol, Dipyridamole may increase the bradycardic activities of Alprenolol.]
[L03AB09, interferon alfacon-1, The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon alfacon-1.]
[G04BE01, alprostadil, The risk or severity of hypotension and priapism can be increased when Dipyridamole is combined with Alprostadil.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Dipyridamole.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Dipyridamole.]
[C09AA16, imidapril, Dipyridamole may increase the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Dipyridamole.]
[S01EB07, isoflurophate, The therapeutic efficacy of Isoflurophate can be decreased when used in combination with Dipyridamole.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Dipyridamole.]
[C05AE02, isosorbide dinitrate, The risk or severity of hypotension can be increased when Dipyridamole is combined with Isosorbide dinitrate.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Isoxsuprine.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Bivalirudin.]
[C04AF01, kininogenase, The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Dipyridamole.]
[N01AX03, ketamine, The therapeutic efficacy of Ketamine can be decreased when used in combination with Dipyridamole.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Dipyridamole.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Dipyridamole is combined with Prasugrel.]
[J02AB02, ketoconazole, Ketoconazole may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N05AH03, olanzapine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Dipyridamole.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding can be increased when Dipyridamole is combined with Deferasirox.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Dipyridamole.]
[C07AG01, labetalol, Dipyridamole may increase the bradycardic activities of Labetalol.]
[C02AA05, deserpidine, Dipyridamole may increase the antihypertensive activities of Deserpidine.]
[N07AA30, ambenonium, The therapeutic efficacy of Ambenonium can be decreased when used in combination with Dipyridamole.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dipyridamole.]
[L01DC03, mitomycin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Mitomycin.]
[G03AD01, levonorgestrel, The risk or severity of adverse effects can be increased when Levonorgestrel is combined with Dipyridamole.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Dipyridamole is combined with Levodopa.]
[C01EB21, regadenoson, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Regadenoson.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Dipyridamole.]
[L01AD02, lomustine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Lomustine.]
[C10AA02, lovastatin, Lovastatin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[G03DC03, lynestrenol, The risk or severity of adverse effects can be increased when Lynestrenol is combined with Dipyridamole.]
[L01EG01, temsirolimus, The risk or severity of bleeding can be increased when Dipyridamole is combined with Temsirolimus.]
[P03AX03, malathion, The therapeutic efficacy of Malathion can be decreased when used in combination with Dipyridamole.]
[L01EA03, nilotinib, The risk or severity of bleeding can be increased when Dipyridamole is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Mannitol is combined with Dipyridamole.]
[C02BB01, mecamylamine, Dipyridamole may increase the antihypertensive activities of Mecamylamine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Mechlorethamine can be decreased when used in combination with Dipyridamole.]
[M02AA18, meclofenamic acid, The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Dipyridamole.]
[G03DB03, medrogestone, Medrogestone may decrease the anticoagulant activities of Dipyridamole.]
[P01BC02, mefloquine, The therapeutic efficacy of Mefloquine can be decreased when used in combination with Dipyridamole.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Dalteparin.]
[L01AA03, melphalan, The risk or severity of bleeding can be increased when Dipyridamole is combined with Melphalan.]
[N06DX01, memantine, The therapeutic efficacy of Memantine can be decreased when used in combination with Dipyridamole.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Dipyridamole.]
[N05AX13, paliperidone, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Paliperidone.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Methazolamide is combined with Dipyridamole.]
[H03BB02, methimazole, Methimazole may increase the anticoagulant activities of Dipyridamole.]
[L01BA04, pemetrexed, The risk or severity of bleeding can be increased when Dipyridamole is combined with Pemetrexed.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Dipyridamole.]
[L04AX03, methotrexate, The risk or severity of bleeding can be increased when Dipyridamole is combined with Methotrexate.]
[N05AA02, methotrimeprazine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Methotrimeprazine.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dipyridamole.]
[C02AB01, methyldopa, Dipyridamole may increase the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Dipyridamole.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dipyridamole.]
[C03BA08, metolazone, Dipyridamole may increase the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, Dipyridamole may increase the bradycardic activities of Metoprolol.]
[N02BB03, aminopyrine, The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Dipyridamole.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Parnaparin.]
[G03XB01, mifepristone, The risk or severity of adverse effects can be increased when Mifepristone is combined with Dipyridamole.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Tinzaparin.]
[C09CA03, valsartan, Dipyridamole may increase the antihypertensive activities of Valsartan.]
[D11AX01, minoxidil, Dipyridamole may increase the antihypertensive activities of Minoxidil.]
[L01DB07, mitoxantrone, The risk or severity of bleeding can be increased when Dipyridamole is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dipyridamole.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Dipyridamole.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Dipyridamole.]
[J01DD06, moxalactam, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Latamoxef.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Dipyridamole.]
[G04CA04, silodosin, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Silodosin.]
[G03XC01, raloxifene, The excretion of Raloxifene can be decreased when combined with Dipyridamole.]
[N06AA17, amoxapine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Amoxapine.]
[L03AB08, interferon beta-1b, The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon beta-1b.]
[C07AA12, nadolol, Dipyridamole may increase the bradycardic activities of Nadolol.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Dipyridamole.]
[M02AA12, naproxen, The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Dipyridamole.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Dipyridamole is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Dipyridamole.]
[L01CD02, docetaxel, The risk or severity of bleeding can be increased when Dipyridamole is combined with Docetaxel.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Dipyridamole.]
[A10BX02, repaglinide, Repaglinide may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Levosimendan is combined with Dipyridamole.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Dipyridamole.]
[S01EB06, neostigmine, The therapeutic efficacy of Neostigmine can be decreased when used in combination with Dipyridamole.]
[N05AX14, iloperidone, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Dipyridamole.]
[N06AX23, desvenlafaxine, The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Dipyridamole.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Amsacrine.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Dipyridamole.]
[C08CA04, nicardipine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Nicardipine.]
[C04AE02, nicergoline, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Nicergoline.]
[C08CA05, nifedipine, The risk or severity of hypotension can be increased when Dipyridamole is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Dipyridamole.]
[V03AB22, amyl nitrite, The risk or severity of hypotension can be increased when Dipyridamole is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Dipyridamole may increase the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Dipyridamole may increase the antihypertensive activities of Nisoldipine.]
[C08CA08, nitrendipine, Dipyridamole may decrease the excretion rate of Nitrendipine which could result in a higher serum level.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Dipyridamole.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Pramipexole is combined with Dipyridamole.]
[C02DD01, nitroprusside, Dipyridamole may increase the antihypertensive activities of Nitroprusside.]
[G03DC02, norethindrone, The risk or severity of adverse effects can be increased when Norethisterone is combined with Dipyridamole.]
[G03AC07, norgestrienone, The risk or severity of adverse effects can be increased when Norgestrienone is combined with Dipyridamole.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N06AA10, nortriptyline, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Nortriptyline.]
[A16AX07, sapropterin, Sapropterin may increase the hypotensive activities of Dipyridamole.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Dipyridamole.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Reviparin.]
[S02AA16, ofloxacin, Dipyridamole may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Dipyridamole is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Dipyridamole is combined with Ancrod.]
[G04CA02, tamsulosin, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Tamsulosin.]
[C01AC01, ouabain, The excretion of Ouabain can be decreased when combined with Dipyridamole.]
[C07AA02, oxprenolol, Dipyridamole may increase the bradycardic activities of Oxprenolol.]
[S01BC02, oxyphenbutazone, The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Dipyridamole.]
[J04AA01, aminosalicylic acid, The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dipyridamole.]
[N05AH05, asenapine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Dipyridamole is combined with Danaparoid.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be decreased when used in combination with Dipyridamole.]
[G03DB06, chlormadinone, The risk or severity of adverse effects can be increased when Chlormadinone is combined with Dipyridamole.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Papaverine.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Dipyridamole.]
[C07AA23, penbutolol, Dipyridamole may increase the bradycardic activities of Penbutolol.]
[M01CC01, penicillamine, The risk or severity of bleeding can be increased when Dipyridamole is combined with Penicillamine.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Dipyridamole.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Dipyridamole.]
[L01XX08, pentostatin, The risk or severity of bleeding can be increased when Dipyridamole is combined with Pentostatin.]
[C04AD03, pentoxifylline, The therapeutic efficacy of Dipyridamole can be increased when used in combination with Pentoxifylline.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Dipyridamole.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Dipyridamole is combined with Phenindione.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Dipyridamole.]
[C04AX02, phenoxybenzamine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Phenoxybenzamine.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Dipyridamole is combined with Phenprocoumon.]
[V03AB36, phentolamine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Dipyridamole.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be decreased when Dipyridamole is combined with Phenylephrine.]
[V03AB19, physostigmine, The therapeutic efficacy of Physostigmine can be decreased when used in combination with Dipyridamole.]
[C08CX01, mibefradil, Dipyridamole may increase the antihypertensive activities of Mibefradil.]
[C07AA03, pindolol, Dipyridamole may increase the bradycardic activities of Pindolol.]
[C10AA05, atorvastatin, Dipyridamole may decrease the excretion rate of Atorvastatin which could result in a higher serum level.]
[J05AE01, saquinavir, Dipyridamole may decrease the excretion rate of Saquinavir which could result in a higher serum level.]
[C09CA02, eprosartan, Dipyridamole may increase the antihypertensive activities of Eprosartan.]
[S01BC06, piroxicam, The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Dipyridamole.]
[J01DD16, cefditoren, The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefditoren.]
[N02CX01, pizotyline, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Pizotifen.]
[C09CA04, irbesartan, Dipyridamole may increase the antihypertensive activities of Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Dipyridamole.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Dipyridamole is combined with Alteplase.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[C03AA05, polythiazide, Dipyridamole may increase the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Dipyridamole can be increased when it is combined with Ritonavir.]
[V03AB21, potassium iodide, Potassium Iodide may increase the anticoagulant activities of Dipyridamole.]
[C10AA08, pitavastatin, Dipyridamole may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C07AB01, practolol, Dipyridamole may increase the bradycardic activities of Practolol.]
[C02CA01, prazosin, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Prazosin.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Dipyridamole.]
[C01BA02, procainamide, The therapeutic efficacy of Procainamide can be decreased when used in combination with Dipyridamole.]
[S01HA05, procaine, The therapeutic efficacy of Procaine can be decreased when used in combination with Dipyridamole.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Dipyridamole.]
[C10AB05, fenofibrate, Dipyridamole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N05AA03, promazine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Promazine.]
[G03DB07, promegestone, Promegestone may decrease the anticoagulant activities of Dipyridamole.]
[C01BC03, propafenone, Dipyridamole may increase the bradycardic activities of Propafenone.]
[R06AX26, fexofenadine, The excretion of Fexofenadine can be decreased when combined with Dipyridamole.]
[N05AC01, periciazine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Periciazine.]
[N05CM06, propiomazine, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Propiomazine.]
[L01XH02, romidepsin, The excretion of Romidepsin can be decreased when combined with Dipyridamole.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Dipyridamole.]
[C07AA05, propranolol, Dipyridamole may increase the bradycardic activities of Propranolol.]
[H03BA02, propylthiouracil, Propylthiouracil may increase the anticoagulant activities of Dipyridamole.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Dipyridamole is combined with Epoprostenol.]
[N05AX12, aripiprazole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Aripiprazole.]
[S01EB03, ecothiopate, The therapeutic efficacy of Echothiophate can be decreased when used in combination with Dipyridamole.]
[M09AB02, collagenase Clostridium histolyticum, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Collagenase clostridium histolyticum.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Dipyridamole.]
[C01BA01, quinidine, The therapeutic efficacy of Dipyridamole can be increased when used in combination with Quinidine.]
[P01BC01, quinine, The therapeutic efficacy of Dipyridamole can be increased when used in combination with Quinine.]
[C02AA01, rescinnamine, Dipyridamole may increase the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[J04AB02, rifampin, Rifampicin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N02BA05, salicylamide, The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Dipyridamole.]
[A07EC01, sulfasalazine, The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Dipyridamole.]
[S01BC08, salicylic acid, The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Dipyridamole.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Dipyridamole.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Dipyridamole.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Obinutuzumab.]
[V04CC03, sincalide, The excretion of Sincalide can be decreased when combined with Dipyridamole.]
[C07AA07, sotalol, Dipyridamole may increase the bradycardic activities of Sotalol.]
[L01CD04, cabazitaxel, The risk or severity of bleeding can be increased when Dipyridamole is combined with Cabazitaxel.]
[C03DA01, spironolactone, Spironolactone may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[B02BD14, antihemophilic factor, porcine B-domain truncated recombinant, The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Dipyridamole.]
[A05AA01, chenodeoxycholic acid, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Chenodeoxycholic acid.]
[D11AX24, deoxycholic acid, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Deoxycholic acid.]
[B02BD11, coagulation factor XIII a-subunit (recombinant), The therapeutic efficacy of Catridecacog can be decreased when used in combination with Dipyridamole.]
[B02BB01, fibrinogen, human, The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Dipyridamole.]
[C01DA14, isosorbide mononitrate, Dipyridamole may increase the vasodilatory activities of Isosorbide mononitrate.]
[A05AA02, ursodiol, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ursodeoxycholic acid.]
